

Global consultation of National Leprosy Programme managers, partners and affected persons on Global Leprosy Strategy 2021–2030

Report of the virtual meeting
26-30 October 2020

Global consultation of National Leprosy Programme managers, partners and affected persons on Global Leprosy Strategy 2021–2030: Report of the virtual meeting 26-30 October 2020.

ISBN: 978-92-9022-822-6

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Leprosy: Global consultation of National Leprosy Programme managers, partners and affected persons on Global Leprosy Strategy 2021–2030: Report of the virtual meeting 26-30 October 2020. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in India.

Table of contents

Abbreviations.....	vi
1. Inaugural session	1
1.1. Inaugural address by the Regional Director, WHO South-East Asia Region.....	1
1.2. Message by the WHO Goodwill Ambassador for Leprosy Elimination.....	2
2. Global leprosy situation	2
2.1. Overview of current global situation.....	2
2.2. Challenges faced in countries	4
2.2.1. <i>Brazil</i>	4
2.2.2. <i>Ethiopia</i>	5
2.2.3. <i>India</i>	5
2.2.4. <i>Federated States of Micronesia</i>	6
2.2.5. <i>The Philippines</i>	6
2.2.6. <i>Somalia</i>	7
3. Global Leprosy Strategy 2021–2030	8
3.1. Current draft of the Global Leprosy Strategy 2021–2030	8
3.2. General comments by the Technical and Advisory Group on Leprosy.....	9
4. Global normative guidance documents.....	10
4.1. Roadmap for Neglected Tropical Diseases, 2021–2030	11
4.2. Global Framework for Multi-Disease Elimination	11
5. Contact tracing and post-exposure prophylaxis	12
5.1. WHO guidance and next steps	12
5.2. Country perspectives on contact tracing and PEP.....	14
5.2.1. <i>Colombia</i>	14
5.2.2. <i>Ghana</i>	15
5.2.3. <i>India</i>	15
5.2.4. <i>Indonesia</i>	16
5.2.5. <i>Kiribati</i>	16
5.2.6. <i>United Republic of Tanzania</i>	17
5.3. Perspectives of persons affected by leprosy on contact tracing and post-exposure prophylaxis.....	18
5.3.1. <i>Perspectives of affected persons: ENAPAL</i>	19
5.3.2. <i>Perspectives of affected persons: IDEA-Nepal</i>	19
5.3.3. <i>Perspectives of affected persons: MORHAN</i>	20
5.3.4. <i>Perspectives of affected persons: Papua New Guinea</i>	20
5.4. Partner perspectives on contact tracing and/or PEP	20
5.4.1. <i>Partner perspectives: ALM</i>	21
5.4.2. <i>Partner perspectives: GLRA</i>	21
5.4.3. <i>Partner perspectives: PLF</i>	22

6. Disability care.....	23
6.1. Country perspectives on disability care in leprosy	23
6.1.1. <i>Bangladesh</i>	23
6.1.2. <i>China</i>	24
6.1.3. <i>Democratic Republic of the Congo</i>	25
6.1.4. <i>Myanmar</i>	25
6.1.5. <i>Paraguay</i>	26
6.1.6. <i>Russian Federation</i>	26
6.2. Perspective of persons affected on disability care in leprosy	27
6.2.1. <i>Perspective of affected persons: APAL India</i>	27
6.2.2. <i>Perspective of affected persons: HANDA China</i>	28
6.2.3. <i>Perspective of affected persons: MORHAN Brazil</i>	28
6.3. Partner perspectives on disability care in leprosy.....	29
6.3.1. <i>Partner perspectives: ANESVAD</i>	29
6.3.2. <i>Partner perspectives: LEPRRA Bangladesh</i>	30
6.3.3. <i>Partner perspectives: NLR India Foundation</i>	30
6.3.4. <i>Partner perspectives: TLM</i>	31
7. Interruption of transmission, elimination of disease	31
7.1. Task force on definitions, criteria and indicators for transmission and elimination of leprosy	31
7.1.1. <i>Concepts, definitions and criteria to ascertain elimination of leprosy</i>	31
7.1.2. <i>Indicators and post-elimination surveillance</i>	32
7.2. Interruption of transmission, elimination of disease: country experiences	34
7.2.1. <i>Cuba</i>	34
7.2.2. <i>Japan</i>	34
7.2.3. <i>Maldives</i>	35
7.2.4. <i>Morocco</i>	36
7.3. Country roadmaps for zero leprosy: country perspectives	37
7.3.1. <i>Mexico</i>	37
7.3.2. <i>Nepal</i>	38
7.3.3. <i>South Sudan</i>	39
7.3.4. <i>Viet Nam</i>	40
7.4. Country roadmaps for zero leprosy: perspective of the Global Partnership for Zero Leprosy	40
7.5. Country roadmaps for zero leprosy: comments by expert	41
8. Stigma and discrimination.....	42
8.1. Stigma and discrimination: country perspectives	42
8.1.1. <i>Brazil</i>	42
8.1.2. <i>Malaysia</i>	43
8.1.3. <i>Senegal</i>	43
8.1.4. <i>Sri Lanka</i>	44
8.2. Stigma and discrimination: viewpoint of the UN Special Rapporteur.....	45

8.3.	Stigma and discrimination: perspective of partners	46
8.3.1.	<i>Perspective of partners: GLRA Colombia</i>	46
8.3.2.	<i>Perspective of partners: NLR Indonesia</i>	46
8.3.3.	<i>Perspective of partners: TLM India</i>	47
8.3.4.	<i>Perspective of partners: TLM Niger</i>	47
8.4.	Stigma and discrimination: perspective of affected persons	48
8.4.1.	<i>Perspective of affected persons: APAL India</i>	48
8.4.2.	<i>Perspective of affected persons: ILEP Panel of Women and Men Affected by Leprosy</i>	49
8.4.3.	<i>Perspective of affected persons: MORHAN Brazil</i>	49
9.	Research in leprosy	50
10.	Concluding session.....	51
10.1.	Statements by partners	51
10.1.1.	<i>Affected persons</i>	51
10.1.2.	<i>GPZL</i>	52
10.1.3.	<i>ILEP</i>	53
10.1.4.	<i>Novartis</i>	53
10.1.5.	<i>The Nippon Foundation/Sasakawa Health Foundation</i>	53
10.2.	Conclusions and recommendations	54
10.3.	Closing remarks	56
 Annexes 		
Annex 1:	Programme	57
Annex 2:	List of participants	59

Abbreviations

AFR	WHO African Region
ALC	Anti-Leprosy Campaign (Sri Lanka)
ALM	American Leprosy Missions
ALO	Advancing Leprosy and disadvantaged peoples Opportunities Society (Bangladesh)
AMR	anti-microbial resistance
AMR	WHO Americas Region
APAL	Association of People Affected by Leprosy (India)
ASHA	accredited social health activist
BCG	<i>bacille Calmette-Guérin</i>
COVID-19	coronavirus disease 2019
DNA	deoxyribonucleic acid
DR Congo	Democratic Republic of the Congo
EMR	WHO Eastern-Mediterranean Region
ENAPAL	Ethiopian National Association of Persons Affected by Leprosy
EUR	WHO European Region
G2D	grade-2 disability
GLP	Global Leprosy Programme
GLRA	German Tuberculosis and Leprosy Relief Association
GPZL	Global Partnership for Zero Leprosy
HQ	headquarters
IDEA	Integration, Dignity and Economic Advancement
IEC	information, education, communication
ILEP	International Federation of Anti-Leprosy Associations
LEPRA	British Leprosy Relief Association
LRI	Leprosy Research Initiative
MB	multi-bacillary
MDT	multidrug therapy
MORHAN	Movement of Reintegration of Persons Afflicted by Hansen's Disease (Brazil)
NGO	nongovernmental organization
NTD	neglected tropical disease
NLP	national leprosy programme
NLR	Until No Leprosy Remains
PAHO	Pan-American Health Organization
PB	pauci-bacillary

PCR	polymerase chain reaction
PEP	post-exposure prophylaxis
PLF	Pacific Leprosy Foundation
SDG	sustainable development goal
SDR	single-dose rifampicin
SEAR	WHO South-East Asia Region
SHF	Sasakawa Health Foundation
TAG	Technical and Advisory Group
TB	tuberculosis
TFCEL	Task Force on definitions, criteria and indicators for transmission and elimination of leprosy
TLM	The Leprosy Mission
TLMTI	The Leprosy Mission Trust India
TNF	The Nippon Foundation
UHC	universal health coverage
UN	United Nations
WASH	water, sanitation and hygiene
WHO	World Health Organization
WPR	WHO Western Pacific Region

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24242

